Literature DB >> 28948861

Prophylaxis of human toxoplasmosis: a systematic review.

Senaka Rajapakse1,2, Praveen Weeratunga1,2, Chaturaka Rodrigo2,3, Nipun Lakshitha de Silva1,4, Sumadhya Deepika Fernando5.   

Abstract

Toxoplasmosis is an infection caused by the intracellular protozoan parasite Toxoplasma gondii, and is associated with clinically significant infection in immunocompromised individuals. Vertical transmission during pregnancy can manifest as congenital toxoplasmosis in the neonate, and can have serious consequences. This review aims to describe the modalities for prophylaxis of toxoplasmosis in susceptible populations, and focuses on the following: (1) prophylaxis of congenital toxoplasmosis; (2) prophylaxis of toxoplasmosis in patients with HIV/AIDS; and (3) prophylaxis of toxoplasmosis in transplant recipients.

Entities:  

Keywords:  HIV; Toxoplasmosis; congenital; immunocompromised; prophylaxis; transplant

Mesh：

Year:  2017        PMID： 28948861      PMCID： PMC5694886          DOI： 10.1080/20477724.2017.1370528

Source DB:  PubMed          Journal:  Pathog Glob Health        ISSN： 2047-7724            Impact factor:   2.894


  43 in total

1.  Comparison of high and low doses of trimethoprim-sulfamethoxazole for primary prevention of toxoplasmic encephalitis in human immunodeficiency virus-infected patients.

Authors:  E Ribera; A Fernandez-Sola; C Juste; A Rovira; F J Romero; L Armadans-Gil; I Ruiz; I Ocaña; A Pahissa
Journal:  Clin Infect Dis       Date:  1999-12       Impact factor: 9.079

2.  Risk factors for Toxoplasma gondii infection in pregnancy. Results of a prospective case-control study in Norway.

Authors:  G Kapperud; P A Jenum; B Stray-Pedersen; K K Melby; A Eskild; J Eng
Journal:  Am J Epidemiol       Date:  1996-08-15       Impact factor: 4.897

Review 3.  Infectious complications among 620 consecutive heart transplant patients at Stanford University Medical Center.

Authors:  J G Montoya; L F Giraldo; B Efron; E B Stinson; P Gamberg; S Hunt; N Giannetti; J Miller; J S Remington
Journal:  Clin Infect Dis       Date:  2001-08-06       Impact factor: 9.079

4.  Meta-analysis of prophylactic treatments against Pneumocystis carinii pneumonia and toxoplasma encephalitis in HIV-infected patients.

Authors:  H C Bucher; L Griffith; G H Guyatt; M Opravil
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1997-06-01

5.  Once-weekly administration of dapsone/pyrimethamine vs. aerosolized pentamidine as combined prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus-infected patients.

Authors:  M Opravil; B Hirschel; A Lazzarin; A Heald; M Pechère; S Rüttimann; A Iten; J von Overbeck; D Oertle; G Praz
Journal:  Clin Infect Dis       Date:  1995-03       Impact factor: 9.079

6.  Primary prophylaxis with pyrimethamine for toxoplasmic encephalitis in patients with advanced human immunodeficiency virus disease: results of a randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS.

Authors:  M A Jacobson; C L Besch; C Child; R Hafner; J P Matts; K Muth; D N Wentworth; J D Neaton; D Abrams; D Rimland
Journal:  J Infect Dis       Date:  1994-02       Impact factor: 5.226

Review 7.  [Prophylaxis against Toxoplasma gondii disease in pediatric and adult patients undergoing solid organ and hematopoietic stem cells transplantation].

Authors:  Ernesto Payá; Isabel Noemí; Renzo Tassara; Paula Catalán; Carmen L Avilés
Journal:  Rev Chilena Infectol       Date:  2012-09       Impact factor: 0.520

8.  Dapsone-pyrimethamine compared with aerosolized pentamidine as primary prophylaxis against Pneumocystis carinii pneumonia and toxoplasmosis in HIV infection. The PRIO Study Group.

Authors:  P M Girard; R Landman; C Gaudebout; R Olivares; A G Saimot; P Jelazko; C Gaudebout; A Certain; F Boué; E Bouvet
Journal:  N Engl J Med       Date:  1993-05-27       Impact factor: 91.245

9.  Aerosolized pentamidine, cotrimoxazole and dapsone-pyrimethamine for primary prophylaxis of Pneumocystis carinii pneumonia and toxoplasmic encephalitis.

Authors:  A Antinori; R Murri; A Ammassari; A De Luca; A Linzalone; A Cingolani; F Damiano; G Maiuro; J Vecchiet; G Scoppettuolo
Journal:  AIDS       Date:  1995-12       Impact factor: 4.177

10.  Assessment of laboratory methods used in the diagnosis of congenital toxoplasmosis after maternal treatment with spiramycin in pregnancy.

Authors:  Isolina Mx Rodrigues; Tatiane L Costa; Juliana B Avelar; Waldemar N Amaral; Ana M Castro; Mariza M Avelino
Journal:  BMC Infect Dis       Date:  2014-06-24       Impact factor: 3.090
View more
  12 in total

1.  Toxoplasma gondii infection and insomnia: A case control seroprevalence study.

Authors:  Cosme Alvarado-Esquivel; Sergio Estrada-Martínez; Alma Rosa Pérez-Álamos; Agar Ramos-Nevárez; Karina Botello-Calderón; Ángel Osvaldo Alvarado-Félix; Raquel Vaquera-Enríquez; Gustavo Alexis Alvarado-Félix; Antonio Sifuentes-Álvarez; Carlos Alberto Guido-Arreola; Elizabeth Rábago-Sánchez; Leandro Saenz-Soto
Journal:  PLoS One       Date:  2022-06-09       Impact factor: 3.752

Review 2.  Treatment of Toxoplasmosis: Historical Perspective, Animal Models, and Current Clinical Practice.

Authors:  Ildiko Rita Dunay; Kiran Gajurel; Reshika Dhakal; Oliver Liesenfeld; Jose G Montoya
Journal:  Clin Microbiol Rev       Date:  2018-09-12       Impact factor: 26.132

3.  Toxoplasma gondii exposure and epilepsy: A matched case-control study in a public hospital in northern Mexico.

Authors:  Cosme Alvarado-Esquivel; Yazmin Del Rosario Rico-Almochantaf; Jesús Hernández-Tinoco; Gerardo Quiñones-Canales; Luis Francisco Sánchez-Anguiano; Jorge Torres-González; Eda Guadalupe Ramírez-Valles; Andrea Minjarez-Veloz
Journal:  SAGE Open Med       Date:  2018-04-10

4.  Molecular Epizootiology of Toxoplasma gondii and Cryptosporidium parvum in the Eastern Oyster (Crassostrea virginica) from Maine (USA).

Authors:  Nicholas D Marquis; Theodore J Bishop; Nicholas R Record; Peter D Countway; José A Fernández Robledo
Journal:  Pathogens       Date:  2019-08-13

5.  In vitro and in vivo Anti-Toxoplasma Effects of Allium sativum Essential Oil Against Toxoplasma gondii RH Strain.

Authors:  Sultan F Alnomasy
Journal:  Infect Drug Resist       Date:  2021-11-30       Impact factor: 4.003

6.  Green synthesis of zinc nanoparticles using Lavandula angustifolia Vera. Extract by microwave method and its prophylactic effects on Toxoplasma gondii infection.

Authors:  Massumeh Saadatmand; Ghaidaa Raheem Lateef Al-Awsi; Abdullah D Alanazi; Asghar Sepahvand; Mojtaba Shakibaie; Saeedeh Shojaee; Rasool Mohammadi; Hossein Mahmoudvand
Journal:  Saudi J Biol Sci       Date:  2021-07-10       Impact factor: 4.219

Review 7.  Congenital Toxoplasmosis: The State of the Art.

Authors:  Lina Bollani; Cinzia Auriti; Cristian Achille; Francesca Garofoli; Domenico Umberto De Rose; Valeria Meroni; Guglielmo Salvatori; Chryssoula Tzialla
Journal:  Front Pediatr       Date:  2022-07-06       Impact factor: 3.569

8.  Toxoplasma gondii infection in pregnant women: a cross-sectional study in Matehuala City, Mexico.

Authors:  Ada-Agustina Sandoval-Carrillo; Angel Antonio Vértiz-Hernández; Jose-Manuel Salas-Pacheco; Olga Edith González-Lugo; Elizabeth-Irasema Antuna-Salcido; Sergio Manuel Salas-Pacheco; Luis Francisco Sánchez-Anguiano; Edna Madai Méndez-Hernández; Jesús Hernández-Tinoco; Francisco Xavier Castellanos-Juárez; Osmel La-Llave-León; Cosme Alvarado-Esquivel
Journal:  BMJ Open       Date:  2020-08-06       Impact factor: 2.692

9.  Treatment of mice with S4B6 IL-2 complex prevents lethal toxoplasmosis via IL-12- and IL-18-dependent interferon-gamma production by non-CD4 immune cells.

Authors:  Andreas Kupz; Saparna Pai; Paul R Giacomin; Jennifer A Whan; Robert A Walker; Pierre-Mehdi Hammoudi; Nicholas C Smith; Catherine M Miller
Journal:  Sci Rep       Date:  2020-08-04       Impact factor: 4.379

Review 10.  Toxoplasmosis: Current and Emerging Parasite Druggable Targets.

Authors:  Rana El Hajj; Lina Tawk; Shaymaa Itani; Maguy Hamie; Jana Ezzeddine; Marwan El Sabban; Hiba El Hajj
Journal:  Microorganisms       Date:  2021-12-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.